First, the association of the use of SGLT2 inhibitors with incident prostate cancer was estimated in diabetic individuals using data derived from electronic health record data in the Shanghai Link Healthcare Database (SLHD; n = 81,122 men with diabetes; Table S1), a representative clinical database covering electronic healthcare records for over 99% of Shanghai residents since 201319 (more details in the STAR Methods, expermential model and subject details). Here, SLC5A2 is linked to prostate carcinoma.